J Hematol Oncol:口服阿扎胞苷治疗缓解期AML患者的不良事件

2021-09-01 Nebula MedSci原创

口服阿扎胞苷维持治疗具有普遍良好的安全性

急性髓性白血病 (AML) 主要发生于老年人,确诊时的中位年龄为 68 岁。大多数通过强化化疗 (IC) 获得形态学缓解的老年 AML 患者最终会复发,而且复发后预后往往较差。

在 QUAZAR AML-001 试验中,与安慰剂相比,口服阿扎胞苷维持治疗可将经 IC 治疗后获得首次缓解但无移植指征的 AML 患者的总生存期延长 9.9 个月(p<0.001),将无复发生存期延长 5.3 个月(p<0.001)。

在QUAZAR AML-001试验中,阿扎胞苷组和安慰剂组的总生存期(A)和无复发生存期(B)

此外,QUAZAR AML-001 试验还提供了与口服阿扎胞苷维持治疗相关的最全面的安全信息,本文汇报了QUAZAR AML-001 试验的主要分析结果

QUAZAR AML-001 试验是一项国际性、安慰剂为对照的随机3期研究,招募了≥ 55岁时确诊的中低危细胞遗传学风险的AML患者,且要求在研究开始前4个月内获得了首次完全缓解(CR)或CR+不完全血细胞计数恢复(CRi)。受试患者被1:1随机分至两组,接受口服阿扎胞苷(300 mg)或安慰剂(1/日),连用14天,28天为一疗程。

两组常见的不良事件

共招募了469位患者,其中238位服用了阿扎胞苷,233位服用了安慰剂。受试患者的中位年龄为 68 岁。患者口服阿扎胞苷或安慰剂的中位疗程分别是12个(范围 1-80)和6个(1-73)。胃肠道不良事件(AE)最为常见,多是低级别的。口服阿扎胞苷治疗过程中最常见的3-4级 AE 是血液性事件。AE 事件很少需要终止口服阿扎胞苷(13%),提示通过使用伴随药物和调整阿扎胞苷剂量就足以有效控制相关不良事件。

血液性不良事件的发生情况

综上所述,口服阿扎胞苷维持治疗具有普遍良好的安全性。建议至少在前两个阿扎胞苷疗程内同步使用止吐剂进行预防,并每隔一周监测一次血细胞计数,并在此后根据需要进行。了解 AML 患者口服阿扎胞苷维持治疗时常见 AE 的类型、发作和持续时间,并实施有效的 AE 管理,可以最大限度地提高治疗依从性,改善生存获益。

原始出处:

Ravandi, F., Roboz, G.J., Wei, A.H. et al. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. J Hematol Oncol 14, 133 (2021). https://doi.org/10.1186/s13045-021-01142-x

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1866211, encodeId=4995186621107, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu May 26 00:18:43 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214297, encodeId=591d121429e69, content=<a href='/topic/show?id=96129e81891' target=_blank style='color:#2F92EE;'>#阿扎胞苷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97818, encryptionId=96129e81891, topicName=阿扎胞苷)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:30:13 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985477, encodeId=753c19854e71a, content=<a href='/topic/show?id=165de9216c8' target=_blank style='color:#2F92EE;'>#缓解期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79216, encryptionId=165de9216c8, topicName=缓解期)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Thu Feb 24 23:18:43 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317646, encodeId=7508131e646a3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Sep 03 10:18:43 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014079, encodeId=16ba10140e9e1, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2af51553538, createdName=zhangyan7217, createdTime=Thu Sep 02 21:47:34 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038415, encodeId=034e1038415d2, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Sep 01 22:18:43 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013545, encodeId=7517101354507, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b97e5473556, createdName=ms1000000696554745, createdTime=Wed Sep 01 20:19:24 CST 2021, time=2021-09-01, status=1, ipAttribution=)]
    2022-05-26 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1866211, encodeId=4995186621107, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu May 26 00:18:43 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214297, encodeId=591d121429e69, content=<a href='/topic/show?id=96129e81891' target=_blank style='color:#2F92EE;'>#阿扎胞苷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97818, encryptionId=96129e81891, topicName=阿扎胞苷)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:30:13 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985477, encodeId=753c19854e71a, content=<a href='/topic/show?id=165de9216c8' target=_blank style='color:#2F92EE;'>#缓解期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79216, encryptionId=165de9216c8, topicName=缓解期)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Thu Feb 24 23:18:43 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317646, encodeId=7508131e646a3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Sep 03 10:18:43 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014079, encodeId=16ba10140e9e1, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2af51553538, createdName=zhangyan7217, createdTime=Thu Sep 02 21:47:34 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038415, encodeId=034e1038415d2, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Sep 01 22:18:43 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013545, encodeId=7517101354507, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b97e5473556, createdName=ms1000000696554745, createdTime=Wed Sep 01 20:19:24 CST 2021, time=2021-09-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1866211, encodeId=4995186621107, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu May 26 00:18:43 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214297, encodeId=591d121429e69, content=<a href='/topic/show?id=96129e81891' target=_blank style='color:#2F92EE;'>#阿扎胞苷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97818, encryptionId=96129e81891, topicName=阿扎胞苷)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:30:13 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985477, encodeId=753c19854e71a, content=<a href='/topic/show?id=165de9216c8' target=_blank style='color:#2F92EE;'>#缓解期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79216, encryptionId=165de9216c8, topicName=缓解期)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Thu Feb 24 23:18:43 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317646, encodeId=7508131e646a3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Sep 03 10:18:43 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014079, encodeId=16ba10140e9e1, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2af51553538, createdName=zhangyan7217, createdTime=Thu Sep 02 21:47:34 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038415, encodeId=034e1038415d2, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Sep 01 22:18:43 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013545, encodeId=7517101354507, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b97e5473556, createdName=ms1000000696554745, createdTime=Wed Sep 01 20:19:24 CST 2021, time=2021-09-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1866211, encodeId=4995186621107, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu May 26 00:18:43 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214297, encodeId=591d121429e69, content=<a href='/topic/show?id=96129e81891' target=_blank style='color:#2F92EE;'>#阿扎胞苷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97818, encryptionId=96129e81891, topicName=阿扎胞苷)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:30:13 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985477, encodeId=753c19854e71a, content=<a href='/topic/show?id=165de9216c8' target=_blank style='color:#2F92EE;'>#缓解期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79216, encryptionId=165de9216c8, topicName=缓解期)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Thu Feb 24 23:18:43 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317646, encodeId=7508131e646a3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Sep 03 10:18:43 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014079, encodeId=16ba10140e9e1, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2af51553538, createdName=zhangyan7217, createdTime=Thu Sep 02 21:47:34 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038415, encodeId=034e1038415d2, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Sep 01 22:18:43 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013545, encodeId=7517101354507, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b97e5473556, createdName=ms1000000696554745, createdTime=Wed Sep 01 20:19:24 CST 2021, time=2021-09-01, status=1, ipAttribution=)]
    2021-09-03 fengyi812
  5. [GetPortalCommentsPageByObjectIdResponse(id=1866211, encodeId=4995186621107, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu May 26 00:18:43 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214297, encodeId=591d121429e69, content=<a href='/topic/show?id=96129e81891' target=_blank style='color:#2F92EE;'>#阿扎胞苷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97818, encryptionId=96129e81891, topicName=阿扎胞苷)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:30:13 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985477, encodeId=753c19854e71a, content=<a href='/topic/show?id=165de9216c8' target=_blank style='color:#2F92EE;'>#缓解期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79216, encryptionId=165de9216c8, topicName=缓解期)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Thu Feb 24 23:18:43 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317646, encodeId=7508131e646a3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Sep 03 10:18:43 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014079, encodeId=16ba10140e9e1, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2af51553538, createdName=zhangyan7217, createdTime=Thu Sep 02 21:47:34 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038415, encodeId=034e1038415d2, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Sep 01 22:18:43 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013545, encodeId=7517101354507, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b97e5473556, createdName=ms1000000696554745, createdTime=Wed Sep 01 20:19:24 CST 2021, time=2021-09-01, status=1, ipAttribution=)]
    2021-09-02 zhangyan7217

    1

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1866211, encodeId=4995186621107, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu May 26 00:18:43 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214297, encodeId=591d121429e69, content=<a href='/topic/show?id=96129e81891' target=_blank style='color:#2F92EE;'>#阿扎胞苷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97818, encryptionId=96129e81891, topicName=阿扎胞苷)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:30:13 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985477, encodeId=753c19854e71a, content=<a href='/topic/show?id=165de9216c8' target=_blank style='color:#2F92EE;'>#缓解期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79216, encryptionId=165de9216c8, topicName=缓解期)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Thu Feb 24 23:18:43 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317646, encodeId=7508131e646a3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Sep 03 10:18:43 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014079, encodeId=16ba10140e9e1, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2af51553538, createdName=zhangyan7217, createdTime=Thu Sep 02 21:47:34 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038415, encodeId=034e1038415d2, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Sep 01 22:18:43 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013545, encodeId=7517101354507, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b97e5473556, createdName=ms1000000696554745, createdTime=Wed Sep 01 20:19:24 CST 2021, time=2021-09-01, status=1, ipAttribution=)]
    2021-09-01 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1866211, encodeId=4995186621107, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu May 26 00:18:43 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214297, encodeId=591d121429e69, content=<a href='/topic/show?id=96129e81891' target=_blank style='color:#2F92EE;'>#阿扎胞苷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97818, encryptionId=96129e81891, topicName=阿扎胞苷)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:30:13 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985477, encodeId=753c19854e71a, content=<a href='/topic/show?id=165de9216c8' target=_blank style='color:#2F92EE;'>#缓解期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79216, encryptionId=165de9216c8, topicName=缓解期)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Thu Feb 24 23:18:43 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317646, encodeId=7508131e646a3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Sep 03 10:18:43 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014079, encodeId=16ba10140e9e1, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2af51553538, createdName=zhangyan7217, createdTime=Thu Sep 02 21:47:34 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038415, encodeId=034e1038415d2, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Sep 01 22:18:43 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013545, encodeId=7517101354507, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b97e5473556, createdName=ms1000000696554745, createdTime=Wed Sep 01 20:19:24 CST 2021, time=2021-09-01, status=1, ipAttribution=)]
    2021-09-01 ms1000000696554745

    1

    0

相关资讯

J Clin Oncol:依维替尼联合阿扎胞苷治疗新确诊的急性髓系白血病

Ivosidenib(依维替尼)是突变型异柠檬酸脱氢酶1(IDH1)的一种口服抑制剂,已获批用于治疗IDH1突变型(mIDH1)急性髓细胞性白血病(AML)。既往研究表明,将阿扎胞苷加入依维替尼可增强

NEJM:阿扎胞苷口服剂用于化疗缓解后老年急性髓系白血病患者的维持治疗

在诱导化疗后实现缓解的急性髓系白血病老年患者,接受阿扎胞苷口服剂 (CC-486)维持治疗可延长总体生存期和无复发生存期

J Clin Oncol:Eprenetapopt联合阿扎胞苷治疗TP53突变型MDS和AML

Eprenetapopt(APR-246)是一种新型的一类药物,可使p53蛋白重构,并重新激活其促凋亡和细胞周期阻滞的功能

J Clin Oncol:Eprenetapopt联合阿扎胞苷治疗TP53突变型MDS

约20%的TP53突变型骨髓增生异常综合征(MDS)患者采用去甲基化药物治疗后可获得完全缓解(CR)。Eprenetapopt联合阿扎胞苷治疗TP53突变型MDS的疗效如何呢?

TP53突变型骨髓增生异常综合症:Eprenetapopt未达到III期研究的主要终点

制药公司Aprea Therapeutics近日表示,一项针对TP53突变型骨髓增生异常综合症患者的III期研究未能达到其完全缓解(CR)率的主要终点。

JCO:口服阿扎胞苷对低风险骨髓增生异常综合征患者的影响

Journal of Clinical Oncology近日发表了一篇研究。结果显示,CC-486虽然可以增加LR-MDS患者不依赖红细胞输血比例,但可能会增加患者早死风险。